NPY rs16147: Stress Coping and Gene Expression
The rs16147 single nucleotide polymorphism is a widely studied functional variant situated in the promoter region of the neuropeptide Y (NPY) gene. Research indicates that it influences transcriptional activity and basal versus stress-induced circulating levels of NPY, a peptide heavily involved in regulating emotional reactivity and autonomic function. While several candidate gene studies associate this variant with differences in stress resilience, anxiety traits, and trauma response, the overall clinical evidence remains limited and observational.
What each genotype means
Higher stress resilience
Research suggests that the T allele is associated with higher levels of neuropeptide Y expression, which may provide a protective effect during periods of high stress. Individuals with this genotype may exhibit greater resilience to traumatic stress and reduced physiological reactivity to trauma cues compared to those with the C allele.
Carried by approximately 22% of individuals in studied cohorts.
Intermediate stress response
This heterozygous genotype represents a mix of the protective T allele and the C allele. Studies indicate that individuals with this genotype may show intermediate levels of neuropeptide Y expression and stress-coping responses, though outcomes often depend on the interaction between genetics and environmental stressors.
Carried by approximately 51% of individuals in studied cohorts.
Potential stress sensitivity
The C allele has been associated in some studies with lower levels of neuropeptide Y expression and increased susceptibility to anxiety or depressive symptoms when exposed to chronic or traumatic stress. This association is complex and depends heavily on environmental factors, so it should not be viewed as a direct indicator of mental health outcomes.
Carried by approximately 27% of individuals in studied cohorts.
Genomic Location and the Molecular Nature of rs16147
The single nucleotide polymorphism rs16147 represents a thymine-to-cytosine substitution (T>C) positioned upstream of the coding sequence in the promoter region of the human NPY gene on chromosome 7. Because it resides within non-coding regulatory DNA rather than an exon, it does not alter the amino acid sequence of the final neuropeptide Y molecule itself. Instead, biophysical and biochemical investigations show that the change alters local DNA curvature and the binding affinity of nuclear transcription factors. Electrophoretic mobility shift assays have demonstrated differential protein complex recruitment between the T and C alleles. Such regulatory shifts can alter promoter efficiency, which in turn influences how effectively RNA polymerase transcribes the gene into messenger RNA in neuronal and peripheral tissues.
Biological Function of Neuropeptide Y
Neuropeptide Y is an abundant 36-amino-acid peptide distributed extensively throughout the central and peripheral nervous systems. In the brain, high concentrations exist within key emotional and behavioral control regions, including the amygdala, hippocampus, and anterior cingulate cortex. Functionally, NPY acts as an endogenous counter-regulatory brake on stress responses, mitigating the excitatory actions of corticotropin-releasing factor. It plays a critical role in balancing the sympathetic nervous system, dampening autonomic hyperarousal, modulating fear extinction, and promoting psychological resilience. Peripherally, NPY influences vasoconstriction, immune signaling, and metabolic homeostasis. As a result, inherited variations that moderate how much NPY is expressed under resting conditions or released during acute challenge have become primary targets for behavioral genetics research.
Research Associations: Stress Resilience, Affect, and Autonomic Tone
Candidate gene investigations have linked rs16147 to intermediate emotional phenotypes, neural reactivity to threat cues, and post-traumatic stress symptom severity. Initial benchmark studies revealed that the T allele correlates with higher stress-induced NPY release, lower neural activation in fear circuits during negative emotional challenges, and reduced post-traumatic stress vulnerability in traumatized cohorts, such as military veterans. Conversely, the C allele has been tied in several interaction studies to heightened trait anxiety, depressive symptoms following childhood adversity, and diminished parasympathetic cardiac vagal outflow under chronic psychological strain. However, evidence strength is classified as limited: candidate gene associations often show tissue-specific or context-dependent expression differences, and large-scale genome-wide association studies (GWAS) have generally failed to detect strong, standalone effects on psychiatric diagnoses.
Interpreting Genetic Results Responsibly
It is critical for consumers and patients to view rs16147 findings as modest statistical tendencies rather than definitive biological destinies. Stress reactivity, autonomic regulation, and vulnerability to mood disorders are deeply polygenic traits governed by thousands of interacting genetic loci, significant epigenetic modifications, and extensive environmental factors. Possessing an allele associated with reduced resilience or higher negative affect does not diagnose an anxiety disorder, predict PTSD, or guarantee difficulty in handling life stressors. Similarly, having a protective genotype does not grant absolute psychological immunity. Commercial genetic testing of rs16147 cannot be used for clinical diagnosis, nor should it influence therapeutic strategies without individualized evaluation by a licensed healthcare provider.
How common is this variant?
The rs16147 variant is common globally, with minor allele frequencies typically ranging between 0.40 and 0.48 across diverse continental populations, meaning that homozygous and heterozygous genotypes are distributed relatively evenly worldwide.
Frequently asked questions
Can my rs16147 genotype predict if I will develop anxiety or PTSD?
No. Complex psychological traits such as anxiety disorders and PTSD are influenced by thousands of genetic variants combined with personal history, trauma exposure, and social support. The rs16147 variant exerts only a minor statistical influence on neuropeptide Y levels, and having a specific genotype cannot predict or diagnose a clinical condition.
Does having the C allele mean I have lower neuropeptide Y levels?
The relationship is nuanced and context-dependent. While some cellular assays and resting-state studies observe differing baseline transcription rates, research indicates that C allele carriers often exhibit lower circulating NPY release during acute stress compared to T allele carriers.
Can I take supplements or medications to change my NPY levels based on my genotype?
Currently, there are no approved over-the-counter supplements or medications designed to modulate NPY expression based on rs16147 genotype. You should never alter prescription medications or start targeted therapies based on consumer genetic test results without consulting a qualified medical provider.
Is rs16147 considered a pathogenic genetic mutation?
No, rs16147 is a benign, natural single nucleotide polymorphism that is highly prevalent in the general population. Because roughly half of the global population carries at least one copy of each allele, it is categorized as a common normal human genetic variation rather than a disease-causing mutation.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs16147?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in NPY
Functional promoter variant in neuropeptide Y that alters expression levels and correlates with neural stress resilience and autonomic responses to stressors.
Regulatory neuropeptide Y promoter polymorphism associated with blunted stress-evoked neuropeptide Y release and increased vulnerability to stress-induced pathology.